Abstract
This chapter reviews studies that have used in silico techniques to design or identify potential HIV-1 entry inhibitors targeting cellular receptors CD4, CCR5, and CXCR4 and envelope glycoproteins, gp120 and gp41 of HIV-1. Both structure- and ligand-based design techniques have been used in those studies by applying diverse modeling techniques such as quantitative structure–activity relationship analysis, conformational analysis, molecular dynamics, pharmacophore generation, docking, virtual screening (using docking software and also shape-based ROCS techniques), and fragment-based design.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Biscone MJ, Pierson TC, Doms RW (2002) Opportunities and challenges in targeting HIV entry. Curr Opin Pharmacol 2:529–533
Starr-Spires LD, Collman RG (2002) HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med 22:681–701
Hertje M, Zhou M, Dietrich U (2010) Inhibition of HIV-1 entry: multiple keys to close the door. ChemMedChem 5:1825–1835
Sodroski JG (1999) HIV-1 entry inhibitors in the side pocket. Cell 99:243–246
Caffrey M (2011) HIV envelope: challenges and opportunities for development of entry inhibitors. Trends Microbiol 19:191–197
Jiang S, Debnath AK (2000) Development of HIV entry inhibitors targeted to the coiled coil regions of gp41. Biochem Biophys Res Commun 269:641–646
Jiang S, Zhao Q, Debnath AK (2002) Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 8:563–580
Vita C, Drakopoulou E, Vizzavona J et al (1999) Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci USA 96:13091–13096
Wyatt R, Kwong PD, Desjardins E et al (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705–711
Martin L, Stricher F, Misse D et al (2003) Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 21:71–76
Li H, Guan Y, Szczepanska A et al (2007) Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins. Bioorg Med Chem 15:4220–4228
Zhao Q, Ma L, Jiang S et al (2005) Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213–225
Madani N, Schon A, Princiotto AM et al (2008) Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16:1689–1701
Yoshimura K, Harada S, Shibata J et al (2010) Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 84:7558–7568
Lalonde JM, Elban MA, Courter JR et al (2011) Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem 19:91–101
Yamada Y, Ochiai C, Yoshimura K et al (2010) CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett 20:354–358 16a.Kwon YD, Finzi A, Wu X et al (2012) Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci USA 109:5663–5668
Jones G, Willett P, Glen RC (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 245:43–53
Verdonk ML, Cole JC, Hartshorn MJ et al (2003) Improved protein-ligand docking using GOLD. Proteins 52:609–623
Grant JA, Gallardo MA, Pickup BT (1996) A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape. J Comput Chem 17:1653–1666
Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749
Halgren TA, Murphy RB, Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759
Caporuscio F, Tafi A, Gonzalez E et al (2009) A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions. Bioorg Med Chem Lett 19:6087–6091
Cornell WD, Cieplak P, Bayly CI et al (1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117:5179–5197
Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849–857
Boyd MR, Gustafson KR, McMahon JB et al (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 41:1521–1530
Dey B, Lerner DL, Lusso P et al (2000) Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 74:4562–4569
Esser MT, Mori T, Mondor I et al (1999) Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 73:4360–4371
Patsalo V, Raleigh DP, Green DF (2011) Rational and computational design of stabilized variants of cyanovirin-N that retain affinity and specificity for glycan ligands. Biochemistry 50:10698–10712
Neffe AT, Meyer B (2004) A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Angew Chem Int Ed Engl 43:2937–2940
Wulfken J (2000) Development of CD4 binding peptides as inhibitors of HIV infection. Ph.D. Thesis, University of Hamburg, Germany
Neffe AT, Bilang M, Gruneberg I, Meyer B (2007) Rational optimization of the binding affinity of CD4 targeting peptidomimetics with potential anti HIV activity. J Med Chem 50:3482–3488
Lee DY, Lin X, Paskaleva EE et al (2009) Palmitic acid is a novel CD4 fusion inhibitor that blocks HIV entry and infection. AIDS Res Hum Retroviruses 25:1231–1241
Lin X, Paskaleva EE, Chang W et al (2011) Inhibition of HIV-1 infection in ex vivo cervical tissue model of human vagina by palmitic acid: implications for a microbicide development. PLoS One 6:e24803
Morris GM, Goodsell DS, Halliday RS et al (1998) Automated docking using Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19:1639–1662
Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263–273
Weissenhorn W, Dessen A, Harrison SC et al (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426–430
Lu M, Blacklow SC, Kim PS (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2:1075–1082
Debnath AK, Radigan L, Jiang S (1999) Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem 42:3203–3209
Good AC, Ewing TJ, Gschwend DA, Kuntz ID (1995) New molecular shape descriptors: application in database screening. J Comput Aided Mol Des 9:1–12
Shoichet BK, Bodian DL, Kuntz ID (1992) Molecular docking using shape descriptors. J Comput Chem 13:380–397
Jiang S, Lin K, Lu M (1998) A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J Virol 72:10213–10217
Jiang S, Lu H, Liu S et al (2004) N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 48:4349–4359
Liu B, Joseph RW, Dorsey BD et al (2009) Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation. Bioorg Med Chem Lett 19:5693–5697
Clark M, Meshkat S, Talbot GT et al (2009) Fragment-based computation of binding free energies by systematic sampling. J Chem Inf Model 49:1901–1913
Liu K, Lu H, Hou L et al (2008) Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem 51:7843–7854
Wang Y, Lu H, Zhu Q et al (2010) Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. Bioorg Med Chem Lett 20:189–192
Welch BD, VanDemark AP, Heroux A et al (2007) Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci USA 104:16828–16833
Eckert DM, Malashkevich VN, Hong LH et al (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99:103–115
Tan JJ, Zhang B, Cong XJ et al (2011) Computer-aided design, synthesis, and biological activity evaluation of potent fusion inhibitors targeting HIV-1 gp41. Med Chem 7:309–316
Cong XJ, Tan JJ, Liu M et al (2010) Computational study of binding mode of N-substituted pyrrole derivatives to HIV-1 gp41. Prog Biochem Biophys 37:904–915
Wang CX, Cong XJ, Kong R et al (2010) Binding mode of HIV-1 gp41 with its inhibitor NB-2. J Beijing Univ Technol 36:1118–1123
Kellenberger E, Springael JY, Parmentier M et al (2007) Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem 50:1294–1303
Jain AN (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46:499–511
Farzan M, Choe H, Vaca L et al (1998) A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol 72:1160–1164
Farzan M, Vasilieva N, Schnitzler CE et al (2000) A tyrosine-sulfated peptide based on the N-terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem 275:33516–33521
Farzan M, Mirzabekov T, Kolchinsky P et al (1999) Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96:667–676
Huang CC, Lam SN, Acharya P et al (2007) Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317:1930–1934
Acharya P, Dogo-Isonagie C, Lalonde JM et al (2011) Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. ACS Chem Biol 6:1069–1077
Nardese V, Longhi R, Polo S et al (2001) Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat Struct Biol 8:611–615
Vangelista L, Longhi R, Sironi F et al (2006) Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity. Biochem Biophys Res Commun 351:664–668
Lusso P, Vangelista L, Cimbro R et al (2011) Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J 25:1230–1243
Perez-Nueno VI, Pettersson S, Ritchie DW et al (2009) Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening. J Chem Inf Model 49:810–823
McGann M (2011) FRED pose prediction and virtual screening accuracy. J Chem Inf Model 51:578–596
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Debnath, A.K. (2013). Rational Design of HIV-1 Entry Inhibitors. In: Kortagere, S. (eds) In Silico Models for Drug Discovery. Methods in Molecular Biology, vol 993. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-342-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-62703-342-8_13
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-341-1
Online ISBN: 978-1-62703-342-8
eBook Packages: Springer Protocols